节点文献

盐酸特拉唑嗪片致心房颤动1例分析

One Case of Atrial Fibrillation Caused by Terazosin Tablets

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 郭稳; 邓智建; 张永恒; 郭锦辉;

【Author】 GUO Wen;DENG Zhijian;ZHANG Yongheng;GUO Jinhui;Department of Pharmacy, Huixian People’s Hospital;Department of Clinical Pharmacy, the First Affiliated Hospital of Xinxiang Medical University;Clinical Pharmacy, Henan Province Key Subjects of Medicine, the First Affiliated Hospital of Xinxiang Medical University;

【通讯作者】 郭锦辉;

【机构】 辉县市人民医院药剂科; 新乡医学院第一附属医院临床药学学部; 河南省医学重点学科药学其他学科(临床药学),新乡医学院第一附属医院;

【摘要】 目的 探讨盐酸特拉唑嗪片致心房颤动的不良反应及其机制,为临床合理用药提供参考。方法 对1例使用盐酸特拉唑嗪片治疗高血压合并肾动脉狭窄的病例进行分析,并对相关文献进行归纳和总结。结果 1例52岁女性患者因头晕入院,诊断为脑梗死、高血压3级(极高危)、合并有房间隔膨出瘤、右肾动脉中度狭窄等,给予盐酸特拉唑嗪片1 mg口服后,患者出现心跳加快、心慌等,经心电图示心房颤动,给予美托洛尔缓释片47.5 mg口服,随后不适症状好转。经关联性评价,盐酸特拉唑嗪片致心房颤动为很可能。结论 心房颤动可能是盐酸特拉唑嗪片的潜在不良反应之一,临床治疗过程中,应详细询问患者既往病史、用药史,用药期间严密监测患者心电图等,同时应警惕再次给药后的再激发风险,确保患者用药安全。

【Abstract】 Objective To explore the mechanism through which terazosin tablets induce atrial fibrillation(AF) in order to provide a reference for rational drug use in clinical practice. Methods One case of hypertension complicated with renal artery stenosis treated with terazosin tablets was analyzed based on a literature review. Results A 52-year-old female patient was admitted to the hospital due to dizziness and was diagnosed with cerebral infarction, stage 3 hypertensi on at extremely high risk, accompanied by atrial septal aneurysm and moderate stenosis of the right renal artery. She was administered 1 mg of terazosin tablets orally before she experienced such symptoms as rapid heartbeat and palpitations. An immediate electrocardiogram showed atrial fibrillation. She was given 47.5 mg of metoprolol sustained-release tablets orally, and her symptoms subsequently subsided. Based on correlation evaluation, it was speculated that the patient’s atrial fibrillation might have been caused by terazosin tablets. Conclusion Atrial fibrillation may be one of the potential adverse reactions of terazosin tablets. Therefore, clinicians need to inquire about a patient’s history of disease and previous medications, closely monitor the electrocardiogram, and be alert to the risk of recurrence upon re-administration.

【基金】 中国药学会2024年科普研究重点项目(CMEI2024-KPYJ00610)
  • 【文献出处】 中国药物警戒 ,Chinese Journal of Pharmacovigilance , 编辑部邮箱 ,2025年05期
  • 【分类号】R969
  • 【下载频次】33
节点文献中: 

本文链接的文献网络图示:

本文的引文网络